Exchange: NYSEMkt·Updated 04:46 AM EDT
News
all
press releases
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.
Zacks
More News
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Zacks
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
Zacks
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.
Stocktwits
Biodefense Spotlight Sends Microcap Soaring
As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...
AllPennyStocks.com
Biodefense Spotlight Sends Microcap Soaring
As global health agencies monitor emerging infectious disease threats, interest can return quickly to legacy therapeutic platforms with broad antiviral potential. In biotech, especially among smaller names, previously published research can suddenly become highly relevant when the right real-world catalyst emerges. Shares of AIM ImmunoTech Inc. (NYSE American: AIM) are ripping higher in Tuesday trading, climbing after the company highlighted previously published pre-clinical data supporting the potential use of its lead drug candidate, Ampligen, as a prophylactic or early-intervention ...
AllPennyStocks.com
Why Did AIM Stock Plummet 35% Today?
AIM ImmunoTech announced an agreement with certain accredited investors to exercise outstanding warrants for $0.48 per share to raise $4.2 million in gross proceeds.
Stocktwits
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH
24-7 Market News
Why Did AIM Stock Jump 60% Today?
The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.
Stocktwits

Advertisement|Remove ads.